<DOC>
	<DOCNO>NCT02298829</DOCNO>
	<brief_summary>This Phase 4 non-treatment , long-term follow-up study subject receive AA4500 12-month double blind placebo-controlled study ( AUX CC 803 AUX-CC-804 ) 9-month open label study ( AUX-CC-802 AUX-CC-806 ) sponsor Auxilium Pharmaceuticals , Inc. After participation one aforementioned study , subject follow yearly 4 consecutive long-term follow-up visit least 6 month consecutive visit</brief_summary>
	<brief_title>Long-term Safety , Curvature Deformity Characterization , Immunogenicity Over Time Subjects Previously Treated With AA4500 Peyronies Disease</brief_title>
	<detailed_description>At long-term follow-up visit , subject assess adverse event relative previous long-term follow-up assessment . Blood sample determination antibodies AUX-I AUX-II neutralize antibody AUX-I AUX-II collect long-term follow-up visit . At long-term follow-up visit , flaccid penile examination perform curvature deformity measurement ( penis erect state ) record . Subjects also ask complete Peyronie 's Disease Questionnaire ( PDQ ) International Index Erectile Function ( IIEF ) questionnaire . At visit , medical , surgical , treatment Peyronie 's disease since last assessment also collect record .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Penile Induration</mesh_term>
	<criteria>1 . Have receive least one injection AA4500 complete least first last followup visit one Auxiliumsponsored study ( AUX CC802 , AUXCC803 , AUXCC804 , AUXCC806 ) . 2 . Be able willing comply followup assessment outline protocol , determine investigator . 3 . Voluntarily sign date inform consent agreement approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>curvature</keyword>
	<keyword>bend</keyword>
</DOC>